PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.50%
Net income growth under 50% of AVXL's 50.77%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.
-31.48%
Negative yoy D&A while AVXL is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-66.70%
Negative yoy deferred tax while AVXL stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
10.78%
SBC growth well above AVXL's 8.95%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-179.22%
Negative yoy working capital usage while AVXL is 86.88%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-302.85%
Negative yoy AP while AVXL is 0.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-91.10%
Negative yoy usage while AVXL is 86.88%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
10.78%
Lower 'other non-cash' growth vs. AVXL's 92.46%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-32.84%
Negative yoy CFO while AVXL is 77.87%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-1.01%
Negative yoy CapEx while AVXL is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1225.23%
We reduce yoy other investing while AVXL is 0.00%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
-1611.06%
We reduce yoy invests while AVXL stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both yoy lines negative, with AVXL at -80.91%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.